MX2023003567A - Uso de agonista del receptor de esfingosina-1-fosfato. - Google Patents

Uso de agonista del receptor de esfingosina-1-fosfato.

Info

Publication number
MX2023003567A
MX2023003567A MX2023003567A MX2023003567A MX2023003567A MX 2023003567 A MX2023003567 A MX 2023003567A MX 2023003567 A MX2023003567 A MX 2023003567A MX 2023003567 A MX2023003567 A MX 2023003567A MX 2023003567 A MX2023003567 A MX 2023003567A
Authority
MX
Mexico
Prior art keywords
sphingosine
receptor agonist
phosphate receptor
phosphate
prevention
Prior art date
Application number
MX2023003567A
Other languages
English (en)
Inventor
Tae Hun Kim
Ki Chan Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023003567A publication Critical patent/MX2023003567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona al uso de un compuesto de la fórmula química 1 o una sal farmacéuticamente aceptable del mismo para la prevención o tratamiento de dermatitis atópica.
MX2023003567A 2020-09-28 2021-09-27 Uso de agonista del receptor de esfingosina-1-fosfato. MX2023003567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200125583 2020-09-28
PCT/KR2021/013097 WO2022065939A1 (ko) 2020-09-28 2021-09-27 스핑고신-1-인산 수용체 효능제의 용도

Publications (1)

Publication Number Publication Date
MX2023003567A true MX2023003567A (es) 2023-04-04

Family

ID=80846731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003567A MX2023003567A (es) 2020-09-28 2021-09-27 Uso de agonista del receptor de esfingosina-1-fosfato.

Country Status (12)

Country Link
US (1) US20230330077A1 (es)
EP (1) EP4212159A4 (es)
JP (1) JP2023542730A (es)
KR (1) KR102703801B1 (es)
CN (1) CN116437921A (es)
AU (1) AU2021349680B2 (es)
BR (1) BR112023005536A2 (es)
CA (1) CA3192701A1 (es)
MX (1) MX2023003567A (es)
TW (2) TW202222314A (es)
WO (1) WO2022065939A1 (es)
ZA (1) ZA202304537B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4324827A4 (en) * 2021-04-14 2024-08-21 Lg Chemical Ltd PHARMACEUTICALLY ACCEPTABLE SALT OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND CRYSTALLINE FORM THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599914A (en) * 2009-11-13 2014-08-29 Receptos Inc Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2390252A1 (en) * 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
DK2958913T3 (en) * 2013-02-20 2018-11-05 Lg Chemical Ltd SPHINGOSIN-1 PHOSPHATRECEPTOR AGONISTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS AN ACTIVE AGENT
EP4445956A2 (en) * 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor

Also Published As

Publication number Publication date
TW202402285A (zh) 2024-01-16
BR112023005536A2 (pt) 2023-04-25
US20230330077A1 (en) 2023-10-19
CN116437921A (zh) 2023-07-14
CA3192701A1 (en) 2022-03-31
JP2023542730A (ja) 2023-10-11
ZA202304537B (en) 2024-07-31
KR102703801B1 (ko) 2024-09-05
EP4212159A1 (en) 2023-07-19
AU2021349680A1 (en) 2023-06-08
KR20220043046A (ko) 2022-04-05
EP4212159A4 (en) 2024-03-06
AU2021349680B2 (en) 2024-09-12
TW202222314A (zh) 2022-06-16
WO2022065939A1 (ko) 2022-03-31

Similar Documents

Publication Publication Date Title
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
TN2020000082A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
ZA202304537B (en) Use of sphingosine-1-phosphate receptor agonist
PH12016500838A1 (en) Isoxazolines as therapeutic agents
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2022012638A (es) Inhibidores de cd38.
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2023003825A (es) Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
PH12019502261A1 (en) Therapeutic or prophylactic agent for peripheral neuropathies
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
SG11201803867TA (en) Sodium channel blocker
MX2023008098A (es) Uso de agonista del receptor de melanocortina-4.
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
MX2020004972A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
MX2022012034A (es) Medicamento para el tratamiento del dolor.
NZ761345A (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2023007429A (es) Uso como agonista selectivo de receptor de melanocortina-4.